Induction of multidrug resistance of acute myeloid leukemia cells by cocultured stromal cells via upregulation of the PI3K/Akt signaling pathway

Oncology Research

Volumn 24, Issue 4, 2016, Pages 215-223

  Chen, Ping ^a   Jin, Qing ^a   Fu, Qiang ^a   You, Peidong ^a   Jiang, Xi ^a   Yuan, Qin ^a   Huang, Huifang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia (AML); HS 5 cells; Multidrug resistance; PI3K Akt signaling pathway

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MULTIDRUG RESISTANCE PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW STROMA CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CELL ADHESION; CHEMOSENSITIVITY; COCULTURE; CONTROLLED STUDY; GENE EXPRESSION; HL 60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL; U937 CELL LINE; UPREGULATION; DRUG RESISTANCE; GENETICS; METABOLISM; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; BIOMARKERS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84981747398     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14634208143021     Document Type: Article

References (31)

1. Macanas, P. P.; Leisewitz, A.; Broekhuizen, R.; Cautivo, K.; Barriga, F. M.; Leisewitz, F.; Gidi, V.; Riquelme, E.; Montecinos, V. P.; Swett, P.; Besa, P.; Ramirez, P.; Ocqueteau, M.; Kalergis, A. M.; Holt, M.; Rettig, M.; DiPersio, J. F.; Nervi, B. Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS One 7:e37203; 2012.
2. + progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Res. 71:4696-4706; 2011.
3. Tabe, Y.; Konopleva, M. Role of microenvironment in resistance of therapy in AML. Curr. Hematol. Malig. Rep. 10:96-103; 2015.
4. 3 and the PI3K/Akt signaling pathway inhibitor LY294002. Pharmazie 70:322-327; 2015.
5. Kip1 axis. Mol. Carcinog. 54:1678-1685; 2015.
6. Tazzari, P. L.; Cappellini, A.; Ricci, F.; Evangelisti, C.; Papa, V.; Grafone, T.; Martinelli, G.; Conte, R.; Cocco, L.; McCubrey, J. A.; Martelli, A. M. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blast. Leukemia 21:427-438; 2007.
7. Martelli, A. M.; Nyakem, M.; Tabellini, G.; Bortul, R.; Tazzari, P. L.; Evangelisti, C.; Cocco, L. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20:911-928; 2006.
8. West, K. A.; Castillo, S. S.; Dennis, P. A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 5:234-248; 2002.
9. Zhinan, Z.; Yushu, H.; Yong, Q. Z. Hematology, 2nd ed. Beijing, China: The Peoples Medical Publishing House; 2012.
10. Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9:667-676; 2004.
11. Costa, C.; Pereira, S.; Lima, L.; Peixoto, A.; Fernandes, E.; Neves, D.; Neves, M.; Gaiteiro, C.; Tavares, A.; Gil da Costa, R. M.; Cruz, R.; Amaro, T.; Oliveira, P. A.; Ferreira, J. A.; Santos, L. L. Abnormal protein glycosylation and activation PI3K/Akt/mTOR pathway: role in bladder cancer prognosis and targeted therapeutics. PLoS One 10:e0141253; 2015.
12. Ying, J.; Xu, Q.; Liu, B.; Zhang, G.; Chen, L.; Pan, H. The expression of the PI3K/Akt/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. Onco. Targets Ther. 8:2427-2433; 2015.
13. Wang, W. L.; Zhang, Y. C.; Zeng, H. M.; Hua, C. L.; Wei, W.; Xu, J.; Zhu, X. F.; Cheng, T.; Yuan, W. P. Regulatory mechanism of PI3K/AKT signaling pathway in acute leukemia. J. Exp. Hematol. 20:18-21; 2012.
14. Ishikawa, F.; Yoshida, S.; Saito, Y.; Hijikata, A.; Kitamura, H.; Tanaka, S.; Nakamura, R.; Tanaka, T.; Tomiyama, H.; Saito, N.; Fukata, M.; Miyamoto, T.; Lyons, B.; Ohshima, K.; Uchida, N.; Taniguchi, S.; Ohara, O.; Akashi, K.; Harada, M.; Shultz, L. D. Chemotherapy-resistant human AML stem cells home to and engraft within the bonemarrow endosteal region. Nat. Biotechnol. 25:1315-1321;2007.
15. Palaiologou, D.; Panayiotidis, P.; Papanikolaou, G.; Georgiou, G.; Boutsikas, G.; Hatzinicolaou, S. L.; Pangalis, G. A.; Sakellaropoulos, N.; Vassilakopoulos, T. P.; Angelopoulou, M. K. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia. Int. J. Lab. Hematol. 37:e7-e10; 2015.
16. de Lima, L. T.; Vivona, D.; Bueno, C. T.; Hirata, M. H.; Luchessi, A. D.; de Castro, F. A.; de Lourdes, F.; Chauffaille, M.; Zanichelli, M. A.; Chiattone, C. S.; Hungria, V. T.; Guerra-Shinohara, E. M. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med. Oncol. 31:851; 2014.
17. Xia, C. Q.; Smith, P. G. Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation. Mol. Pharmacol. 82(6):1008-1021; 2012.
18. Funayama, K.; Murai, F.; Shimane, M.; Nomura, H.; Asano, S. Adhesion-induced drug resistance in leukemia stem cells. Pharmacology 86(2):79-84; 2010.
19. Kubota, Y.; Ohnishi, H.; Kitanaka, A.; Ishida, T.; Tanaka, T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18:1438-1440; 2004.
20. Xu, Q.; Simpson, S. E.; Scialla, T. J.; Bagg, A.; Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102:972-980; 2003.
21. Ramos, A. M.; Fernandez, C.; Amran, D.; Sancho, P.; de Blas, E.; Aller, P. Pharmacologic inhibition of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathion depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105:4013-4020; 2005.
22. Myers, M. P.; Stolarov, J. P.; Eng, C.; Li, J.; Wang, S. I.; Wigler, M. H.; Parsons, R.; Tonks, N. K. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA 94:9052-9057; 1997.
23. Tamura, M.; Gu, J.; Matsumoto, K.; Aota, S.;Parsons, R.; Yamada, M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614-1617; 1998.
24. Karoui, M.; Tresallet, C.; Julie, C.; Zimmermann, U.; Staroz, F.; Brams, A.; Muti, C.; Boulard, C.; Robreau, A. M.; Puy, M.; Malafosse, R.; Penna, C.; Pruvot, F. R.; Thiery, J. P.; Boileau, C.; Rougier, P.; Nordlinger, B.; Radvanyi, F.; Franc, B.; Hofmann-Radvanyi, H. Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1 A in colorectal primary tumors and metastases. Br. J. Cancer 90:1230-1234; 2004.
25. Che, Y. C.; Yao, Q.; Dai, S. Z.; Luo, B.; Wang, Y. Study of the mutation and expression of PTEN gene in endometrial carcinoma and epithelial ovarian cancer. Chin. J. Obstet. Gynecol. 37:608-611; 2002.
26. Colakoglu, T.; Yildirim, S.; Kayaseleuk, F.; Nursal, T. Z.; Ezer, A.; Noyan, T.; Karakayali, H.; Haberal, M. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Am. J. Surg. 195:719-725; 2008.
27. Peng, C.; Chen, Y.; Li, D.; Li, S. Role of Pten in leukemia stem cells. Oncotarget 1:156-160; 2010.
28. Guo, W.; Lasky, J. L.; Chang, C. J.; Mosessian, S.; Lewis, X.; Xiao, Y.; Yeh, J. E.; Chen, J. Y.; Iruela-Arispe, M. L.; Varella-Garcia, M.; Wu, H. Multi-genetic events collaboratively contribute to Pten-null leukemia stem-cell formation. Nature 453:529-533; 2008.
29. Yilmaz, O. H.; Valdez, R.; Theisen, B. K.; Guo, W.; Ferguson, D. O.; Wu, H.; Morrison, S. J. Pten dependence distinguish haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-482; 2006.
30. Hemando, E.; Nahle, Z.; Juan, G.; Diaz-Rodriguez, E.; Alaminos, M.; Hemann, M.; Michel, L.; Mittal, V.; Gerald, W.; Benezra, R.; Lowe, S. W.; Cordon-Card, C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430:797-802; 2004.
31. Ramasamy, R.; Lam, E. W.; Soeiro, I.; Tisato, V.; Bonnet, D.; Dazzi, F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21(2):304-310; 2007.